Risedronate 35 Biotech 35 mg Tablets
PDF Leaflet Revision Date: 01 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of osteoporosis in postmenopausal women.
Dosage (summary)
One 35 mg tablet orally, once a week.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Decreased absorption with food and polyvalent cations
- Increased GI irritation with NSAIDs
Contraindications
- Hypersensitivity to risedronate
- Hypocalcaemia
- Severe renal impairment
Common side effects
- Dyspepsia
- Nausea
- Abdominal pain
- Musculoskeletal pain
Counselling Points
- Take with a full glass of water
- Remain upright for 30 minutes after taking
- Avoid taking with food or certain medications
Serious warnings
- Risk of esophageal irritation
- Osteonecrosis of the jaw
- Atypical femoral fractures
Important Disclaimer
The Risedronate 35 Biotech 35 mg Tablets professional information leaflet below is the property of Biotech Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
